Priority Review for Insmed’s ALIS in rare lung infection

Insmed Inc. (NASDAQ:INSM) said FDA accepted and granted Priority Review to an NDA for ALIS (amikacin liposome inhalation suspension) to treat non-tuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC). The PDUFA date is Sept. 28.

The company said it expects an advisory committee meeting to discuss the NDA...